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21-32 million and 418-456 QALY gained for 25% and 80% uptake. The results were 
sensitive to the proportion of inpatient presentation at ED and utility during influ-
enza. ConClusions: Results clearly demonstrate that both 75 mg BID standard and 
150 mg BID high dose oseltamivir therapy are cost saving. The findings corroborate 
antiviral therapy as being a valuable component of pandemic influenza planning 
decisions in the US.
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objeCtives: To compare the efficacy of Xuebijing injection and ulinastatin injec-
tion for the treatment of inflammation and sepsis by evaluating plasma tumor 
necrosis factor (TNF-α ), interleukin IL-6, procalcitonin (PCT), the average length of 
stay and the average duration of mechanical ventilation. Methods: Literatures 
from January 2004 to August 2013 were retrieved from the online databases such 
as CNKI, CQVIP and Wanfang Data. The documents and data, selected according to 
the inclusion and exclusion criteria, were analyzed by RevMan5.0 Meta-analysis 
software. Results: Four randomized controlled clinical trials were included, 
with 181 patients in the experimental group (Xuebijing +Ulinastatin +based treat-
ment) and 181 patients in the control group (Ulinastatin + basic treatment). Meta-
analysis showed that the tumor necrosis factor TNF-a levels [WMD = -5.16,95% CI 
(-11.07,0.76)] of experimental group and the control group were not statistically 
different, but the interleukin IL-6 levels[WMD= -57.82,95%CI (-112.12, -3.52)] , the 
procalcitonin PCT [WMD= -0.53,95%CI (-0.88, -0.19)] levels , the average length of 
stay [WMD = -3.63,95 % CI (-4.68, -2.58)] and the average duration of mechanical 
ventilation [WMD = -3.77,95% CI (-4.70, -2.83)] of the experimental group and the 
control group were statistically different. ConClusions: Current results indicated 
that the application of Xuebijing injection for the treatment of sepsis provided a 
lower level of interleukin IL-6 and procalcitonin PCT, a shorter length of stay and 
duration of mechanical ventilation.
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objeCtives: This study was conducted to evaluate the effect of a pharmacist ini-
tiated health education programme for improving Hepatitis-B patients’ disease 
state knowledge, attitude, practice and health related quality of life in Quetta city, 
Pakistan. Methods: The study was conducted as non-clinical randomization control 
trial. It was divided into four phases: pre-interventional assessment, training of hospi-
tal pharmacists, development and implementation of the intervention program and 
post-interventional analysis. The pre-interventional phase analysed the Hepatitis-B 
(HB) patients’ knowledge, attitude and practice and current status of Health Related 
Quality of Life (HRQoL). Results: Three hundred and ninety HB patients were tar-
geted for the study. The pre-interventional analysis revealed poor knowledge (mean 
score 8.48 ±2.7 out of 20), negative attitude (mean scores 3.87±1.2 out of 7) and bad 
practice (mean scores 2.37±1.0 out of 8). The HB patients also had poor Health Related 
Quality of Life (mean score of 37.22±30.0 out of 100). The post-interventional data were 
available from 126 patients of interventional group and 151 patients of control group, 
giving a response rate of 64.6% and 77.4% respectively. No significant association was 
observed among demographics variables. However, knowledge, attitude and practice, 
and HRQoL scores were significantly associated (p< 0.001) when compared between 
interventional and control group after the completion of the intervention. There was 
an increase in mean knowledge score (15.46±2.2), attitude score (5.05±1.1), practice 
(5.98±1.1) Health Related Quality of Life (48.16±25.2). The inter-group difference among 
pre- and post- interventional groups reported a significant difference (p< 0.001) when 
knowledge, attitude and practice and HRQoL were compared. ConClusions: The 
educational intervention significantly increase in the HB patients’ knowledge, attitude 
and practice, and HRQoL. Therefore, the role of pharmacists in patient education 
must be formalized and acknowledged as an official part of the health care system.
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objeCtives: The main aims of the study was to estimate the health related qual-
ity of life(HRQOL) between Adverse drug reaction (ADR) and Non ADR retroviral 
patients who are on anti retroviral therapy. Methods: A prospective spontaneous 
, reporting study was conducted over a period of 6 months by clinical pharmacist. 
Each reported ADR was assessed for its causality and severity by using Naranjo ‘s 
scale and Hartwig et al scale .The management of reported ADRs and the treatment 
given for ADR are determined. Health related quality of life is assessed by giving a 
35 item MOS- HIV Questionnare to each individual retroviral patients who are on 
Highly active antiretroviral therapy (HAART) for atleast 45 days by calculating the 
HRQOL score. Results: A Total of 46 ADRs (N= 100) were identified out of which 
30 are males and 16 are females. The assessment by Naranjos scale showed that 
out of 46 ADRs, 8 ADRs were probable, 35 ADRs were possible and 3 ADRs were 
unlikely. Severity assessment by hartwig et al scale showed that 32 ADRs come 
under mild level, 14 ADRs come under moderate level and none come under severe 
level.The Health related quality of life between ADR patients and Non ADR absent 
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objeCtives: Breast milk is considered to give protection against rotavirus infection 
since it contains anti-rotavirus maternal antibodies and other nonspecific inhibi-
tors. Multilevel promotion of breastfeeding is a complex intervention that modifies 
behavioral determinants through multiple levels of health promotion. This interven-
tion can prolong the duration and increase the prevalence of exclusive breastfeed-
ing. This study aims to investigate the effect of multilevel promotion of breastfeeding 
on reducing the required budget for rotavirus vaccination in Indonesia. Methods: 
We developed an age-structured cohort model within a 5-year-time-horizon for the 
2013 Indonesia birth cohort. We compared two situations: (i) baseline, reflecting 
the current situation for the population of under-5-years-old, and (ii) the current 
situation with an additional multilevel promotion of breastfeeding. We used Monte 
Carlo simulations to examine the economic acceptability and affordability of the 
rotavirus vaccination. Results: Vaccination coupled with multilevel promotion 
of breastfeeding could reduce rotavirus-diarrhea by 493,235 cases. At a vaccine 
price of US$ 5.0 per dose, multilevel promotion of breastfeeding could reduce the 
required budget for the implementation of three-dose rotavirus vaccination by US$ 
50,000, compared to the current absence of specific promotion. ConClusions: 
Multilevel promotion of breastfeeding could potentially reduce the required budget 
for rotavirus vaccination. Mortality rate and vaccine price were the most influential 
parameters on the sensitivity analyses.
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objeCtives: The objective of this study is to evaluate the costs-effectiveness of 
introducing pneumococcal conjugate vaccine as part of the childhood immuniza-
tion program in the Philippines. Methods: A cost-utility analysis was conducted 
using a lifetime horizon. A Markov simulation model was used to examine the 
comparative cost-effectiveness of PCV10 and PCV13 against the current scenario 
of no vaccination. A health system perspective was employed to explore different 
funding schemes, which include full or partial vaccination coverage subsidized by 
the government and self-paid vaccination in the private sector. An annual discount 
rate of 3.5% for future costs and outcomes was applied. Results were presented as 
incremental cost-effectiveness ratios (ICERs) per QALY gained. Sensitivity analysis 
was performed to determine the impact of parameter uncertainty. Results: With 
universal vaccination by the government at a cost per dose of Php 624 for PCV10 and 
Php700 for PCV13, the ICER for PCV10 and PCV13 were Php 68,086 and Php 67,631 
per QALY gained, respectively, compared to no vaccination. Partial vaccination of 
25% and 50% of the birth cohort yielded considerably higher ICER values that are 
still below the country ceiling threshold of Php 170,000 per QALY gained, because of 
the loss of herd protection. The analysis also found that with a partial vaccination 
strategy of the government, having at least 10% of the target cohort self-pay a higher 
market price of Php 2.056 for PCV10 and Php 3,545 for PCV13 would make vaccina-
tion cost-ineffective, because of the high out-of-pocket costs. ConClusions: The 
inclusion of PCV in the national immunization program with either universal or 
partial coverage would be a cost-effective intervention in the Philippines compared 
to no vaccination. However, the affordability and sustainability of PCV implementa-
tion over the long term should be considered by decision makers.
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objeCtives: Some recent pharmacological evaluations support that higher expo-
sures of oseltamivir may further reduce duration of influenza viral shedding and 
symptoms. This study investigated the economic impact of oseltamivir standard 
(75 mg BID) and high (150 mg BID) dose treatment and its potential in supporting 
pandemic influenza planning decisions in the US. Methods: A health economic 
(HE) decision analytic model was linked to a pharmacokinetic/pharmacodynamics 
(PK/PD) - transmission dynamic model which simulated the infected population 
in an influenza outbreak under different scenarios. A cost-utility analysis, under 
the US societal perspective, was conducted; comparing oseltamivir 150mg versus 
approved 75mg BID, and no treatment, three levels of uptake (25%, 50%, and 80%), for 
a strain with comparable virulence to typical seasonal-influenza. Model parameters 
such as probabilities, costs (2013 USD), lengths of stay, and utilities were derived 
from published studies. In the HE model, an infected patient was either treated 
with oseltamivir in the outpatient setting or admitted into the hospital, leading 
to no complications, pneumonia, sepsis, and acute respiratory distress syndrome. 
Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness 
ratios (ICERs) were determined over one-year time horizon. Sensitivity analyses 
were undertaken. Results: Under low virulence and low transmissibility scenarios, 
in comparison with no treatment, the use of 75mg BID oseltamivir showed cost-
saving of USD 31-33 million million and 395-452 QALY gained for 25% and 80% 
uptake, respectively. Compared to no treatment, oseltamivir 150 mg BID saved USD 
